RT Journal Article
SR Electronic
T1 Genomic surveillance of SARS-CoV-2 in Thailand reveals mixed imported populations, a local lineage expansion and a virus with truncated ORF7a
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.22.20108498
DO 10.1101/2020.05.22.20108498
A1 Elizabeth M Batty
A1 Theerarat Kochakarn
A1 Bhakbhoom Panthan
A1 Krittikorn Kümpornsin
A1 Poramate Jiaranai
A1 Arporn Wangwiwatsin
A1 Namfon Kotanan
A1 Peera Jaruampornpan
A1 Treewat Watthanachockchai
A1 Kingkan Rakmanee
A1 Insee Sensorn
A1 Somnuek Sungkanuparph
A1 Ekawat Pasomsub
A1 Thanat Chookajorn
A1 Wasun Chantratita
YR 2020
UL http://medrxiv.org/content/early/2020/05/25/2020.05.22.20108498.abstract
AB Coronavirus Disease 2019 (COVID-19) is a global public health threat. Genomic surveillance of SARS-CoV-2 was implemented during March 2020 at a major diagnostic hub in Bangkok, Thailand. Several virus lineages supposedly originated in many countries were found, and a Thai-specific lineage, designated A/Thai-1, has expanded to be predominant in Thailand. A virus sample in the SARS-CoV-2 A/Thai-1 lineage contains a frame-shift deletion at ORF7a, encoding a putative host antagonizing factor of the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work here was supported by Ramathibodi Foundation, TCELS, NRCT and Mahidol University.The computational aspects of this research were supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z and the NIHR Oxford BRC. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EC approval number from Ramathibodi Hospital is MURA2020/676All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available at https://www.gisaid.org/ as described in the manuscript. https://www.gisaid.org/